SEP 25·SEC EDGARMed
Love Douglas purchased $100K of ANNX
Love Douglas (PRESIDENT AND CEO) purchased 26,065 shares of Annexon, Inc. (ANNX) at $3.83 on 2026-09-24.
StockNASDAQ · US · USDHealthcare · Biotechnology
$ANNX
Annexon, Inc.
AlphAI earnings readSecond Quarter 2026 · AUG 12Annexon Reports Second Quarter 2026 Financial Results, Business Updates and Key Anticipated MilestonesVerdict: mixedRead →
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Price · $ANNXvia TradingView
AI sentiment · 7d0 articles
No enriched coverage for $ANNX in the last 7 days.
Insider · 30dAll trades →
- Buys
- $100K 1 txs
- Sells
- — 0 txs
Love Douglas1× · $100K
10b5-1 share of filings0%
Top stories · $ANNXMore →
AUG 22·aol.com
Annexon (ANNX) Q2 2026 Earnings Call Transcript
Annexon (ANNX) reported Q2 2026 earnings with R&D expenses of $46.6M, G&A expenses of $10.6M, and a net loss of $55.3M. The company has $209.2M in cash and a $200M credit facility. Key updates include ARCHER II trial progress in geographic atrophy and plans for a BLA submission for tanruprubart in Q4 2026. Management projects funding into 2028.
AUG 19·fool.com
Annexon (ANNX) Q2 2026 Earnings Call Transcript
Annexon (ANNX) reported Q2 2026 earnings with R&D expenses of $46.6M, G&A expenses of $10.6M, and a net loss of $55.3M. The company has $209.2M in cash and a $200M credit facility. ARCHER II trial for geographic atrophy enrolled 659 patients, exceeding targets. Tanruprubart for Guillain-Barré syndrome (GBS) is on track for BLA submission in Q4 2026, with positive FORWARD study data. Operations are funded into 2028.
ANNX sentiment & insider activity
Recent ANNX coverage spans technology, earnings and insider activity.
In the last 30 days, ANNX insiders filed 1 SEC Form 4 transaction — 1 purchase ($100K) and no sales. The most active reporter was Love Douglas, PRESIDENT AND CEO, with 1 filing.
What's driving ANNX
Insider purchase suggests confidence, potential upside pressure.
The earnings release shows increased R&D spend and a sizable new credit facility, indicating continued cash runway but higher losses, while positive trial enrollment data may support future upside.
Earnings beat expectations on cash runway but increased loss may pressure near-term price.
The endpoint design change can materially affect perceived Phase 3 risk and the probability-weighted path to FDA submission and labeling.
Dual primary endpoint adoption can alter perceived probability of regulatory success and the shape of the risk-reward into upcoming trial readouts and filings.
AlphAI scores every news story that mentions ANNX with an AI model for sentiment and relevance, and aggregates insider trades from Annexon, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $ANNX
Score
Love Douglas purchased $100K of ANNX
Love Douglas (PRESIDENT AND CEO) purchased 26,065 shares of Annexon, Inc. (ANNX) at $3.83 on 2026-09-24.
1 min read
Annexon (ANNX) Q2 2026 Earnings Call Transcript
Annexon (ANNX) reported Q2 2026 earnings with R&D expenses of $46.6M, G&A expenses of $10.6M, and a net loss of $55.3M. The company has $209.2M in cash and a $200M credit facility. Key updates include ARCHER II trial progress in geographic atrophy and plans for a BLA submission for tanruprubart in Q4 2026. Management projects funding into 2028.
3 min read
Annexon (ANNX) Q2 2026 Earnings Call Transcript
Annexon (ANNX) reported Q2 2026 earnings with R&D expenses of $46.6M, G&A expenses of $10.6M, and a net loss of $55.3M. The company has $209.2M in cash and a $200M credit facility. ARCHER II trial for geographic atrophy enrolled 659 patients, exceeding targets. Tanruprubart for Guillain-Barré syndrome (GBS) is on track for BLA submission in Q4 2026, with positive FORWARD study data. Operations are funded into 2028.
3 min read
Annexon, Inc. Q2 2026 Earnings Call Summary
Annexon, Inc. reported Q2 2026 updates on tanruprubart and vonaprument. For ARCHER II in geographic atrophy, management added a month 24 primary endpoint alongside month 15, citing over-enrollment and retention. In FORWARD for GBS, management said rapid benefit was reproduced in Western cohorts. Annexon plans FDA BLA submission for GBS in Q4 2024 and has a $200M credit facility extending runway to 2028.
7 min readAnnexon (ANNX) Is Down 6.1% After Dual Endpoint Shift in ARCHER II Trial - What's Changed
Simply Wall St reports Annexon (ANNX) shares fell about 6.1% after ARCHER II trial updates for vonaprument, including a shift to dual primary endpoints covering 15 and 24 months for geographic atrophy. The article cites Q2 2026 net loss of $55.35 million and says non-dilutive financing up to $200 million extends its cash runway into 2028.
6 min read
Annexon Q2 Earnings Call Highlights
Annexon (NASDAQ:ANNX) reported Q2 call highlights for its complement-targeted therapy tanruprubart in Guillain-Barre syndrome, saying patients showed rapid functional gains and ventilator weaning within days, with adverse events linked to GBS complications. The company also added a 24-month endpoint to ARCHER II for vonaprument, with 15-month review expected in Q4 2026 and results in 2027.
5 min readAnnexon Advances C1q-Targeted Therapies; Tanruprubart BLA Filing And ARCHER II Data On The Horizon
Annexon Biosciences (ANNX) reported Q2 2026 results and clinical updates. It said Phase 3 FORWARD tanruprubart in Guillain-Barre has treated the first 10 U.S. and European patients and expects a Q4 2026 BLA filing. For vonaprument in geographic atrophy, ARCHER II remains on track with Month 15 data in Q4 2026 and final completion in Q3 2027. Q2 R&D was $46.6M, net loss $55.3M. Cash was $209.2M. A $200M credit facility was arranged with $50M drawn.
6 min readSuper Micro jumps premarket on outlook boost, H&R Block surges
U.S. stock futures edged higher ahead of CPI, with investors watching for signals on the Fed’s rate path. In premarket movers, Super Micro Computer rose over 9% on full-year guidance above expectations. H&R Block gained 13.9% after Q4 adjusted EPS of $2.38 vs $2.31 consensus, revenue $3.95B, and FY27 EPS outlook $6.04-$6.24. Other movers included Owlet, Valens Semiconductor, and Riskified.
4 min readAnnexon Biosciences: Annexon Reports Second Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones
Annexon, Inc. (Nasdaq: ANNX) reported Q2 2026 results and clinical updates. It said tanruprubart GBS data support a Q4 2026 BLA submission, and vonaprument GA Phase 3 ARCHER II is on track with a Month 15 endpoint in Q4 2026 and Month 24 in Q3 2027. Cash was $209.2M at June 30, 2026; net loss was $55.3M. It also secured a $200M credit facility.
7 min readAnnexon Biosciences: Annexon Expands Vonaprument Phase 3 Program in Geographic Atrophy with Addition of Month 24 Dual Primary Endpoint Complementing Month 15 Primary Endpoint and Launch of Open-Label
Annexon, Inc. (Nasdaq: ANNX) said it added a Month 24 dual primary endpoint to its Phase 3 ARCHER II trial of vonaprument for geographic atrophy in dry AMD, alongside the existing Month 15 endpoint. It also launched an open-label extension for long-term safety and benefit. Month 15 DMC assessment is expected in Q4 2026, with Month 24 results in Q3 2027.
3 min read